A study published in JAMA Otolaryngology–Head & Neck Surgery found that preoperative chemo-immunotherapy was more effective than immunotherapy alone in reducing tumor size in patients with head and neck cancer. The study analyzed data from 86 adults with head and neck cancer treated between July 2024 and March 2026, and showed that pat...
SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJAMA Otolaryngology–Head & Neck Surgery·DateAug 13, 2026
Recent research explores the use of nanomaterial-based drug delivery to increase treatment efficacy for glioblastoma, a type of brain tumor with poor prognosis. Stimuli-responsive and biomimetic nanomedicines are designed to overcome the blood–brain barrier and deliver drugs selectively within tumors.
SourceChinese Neurosurgical Journal·JournalChinese Neurosurgical Journal·TypeSystematic review·DateAug 12, 2026
Dr. Amoako's evidence-driven services improve early diagnosis, expand access to treatment, and advance locally led research in Ghana. Her work aims to strengthen childhood cancer care across the country.
SourceInstitute for Health Metrics and Evaluation·DateAug 7, 2026
Researchers have developed an experimental drug that tricks cancer cells into consuming more sugar than usual, then blocks their backup fuel source – fat. This approach puts cancer cells under so much stress that many die, demonstrating effectiveness in treating aggressive melanoma in mice.
SourceUniversity of Texas at Austin·JournalNature Chemical Biology·TypeExperimental study·DateAug 5, 2026
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
A cross-sectional study examines trends in US FDA-approved cancer medicines for adult solid tumors between 2006 and 2025. The analysis reveals significant increases in approvals, particularly for original indication approvals.
Circulating circRNAs show high cell-type and tissue specificity, making them ideal for non-invasive cancer management. They can be detected in multiple body fluids and reflect treatment response, positioning them as functional drivers of therapy resistance.
SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateJul 28, 2026
Dr. Yi Li receives CPRIT funding to develop treatments for solitary fibrous tumor, a rare cancer driven by gene fusions. Researchers are working on novel therapies, including immunotherapy and antisense oligonucleotides, to reduce cancer-causing signal activity.
Researchers have developed a new approach to designing drugs that can target multiple types of cancer cells, significantly improving treatment outcomes in mice. By self-assembling into two antibodies that bind together and attack multiple receptors, the modified antibody-drug conjugates outperformed standard treatments.
SourceWashU Medicine·JournalNature·TypeExperimental study·DateJul 15, 2026
Researchers identified why some patients with rare blastic plasmacytoid dendritic cell neoplasm (BPDCN) leukemia don't respond to tagraxofusp. Severe TET2 gene mutations and low TXNRD1 enzyme levels contribute to resistance, suggesting these biomarkers could predict treatment outcomes.
SourceUniversity of Texas M. D. Anderson Cancer Center·JournalLeukemia·DateJul 7, 2026
Sky & Telescope Pocket Sky Atlas, 2nd Edition
Sky & Telescope Pocket Sky Atlas, 2nd Edition is a durable star atlas for planning sessions, identifying targets, and teaching celestial navigation.
A new prodrug and localized drug delivery platform have been developed by researchers to selectively target cancer cells. The platform uses carbamate masking of the 4-anilinoquinazoline hinge nitrogen to modulate exposure and enable controlled activation of EGFR-TKIs in tumour microenvironments.
SourceUniversity of Eastern Finland·JournalBioorganic Chemistry·DateJun 25, 2026
Researchers at Salk Institute uncover an unexpected role for HDAC enzymes in controlling critical genes involved in DNA repair, making pancreatic cells more vulnerable to therapies that induce DNA damage. This finding paves the way for new treatment strategies combining entinostat with DNA-damaging therapies.
SourceSalk Institute·JournalProceedings of the National Academy of Sciences·DateJun 22, 2026
A new study shows that targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare genetic subtype. After two years, 92% of patients remained cancer-free, compared to 61% who received a placebo.
SourceUniversity of California - Los Angeles Health Sciences·JournalNew England Journal of Medicine·DateMay 31, 2026
Researchers at MUSC Hollings Cancer Center have identified a potential way to reduce relapse in medulloblastoma by targeting tumor cells most likely to survive treatment and drive regrowth. The dual-pathway approach, focusing on CK1α, shows promise in preclinical models.
SourceMedical University of South Carolina·JournalCell Death and Disease·TypeExperimental study·DateMay 26, 2026
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
Researchers have identified a hidden mechanism explaining why breast cancer can return years after successful treatment. Slow-growing breast cancer cells can form microscopic tumours that silently tick away in distant organs, evading detection for decades.
SourceGarvan Institute of Medical Research·JournalNature Communications·TypeExperimental study·DateMay 11, 2026
A NIH-funded study discovered that testosterone may play a key role in limiting brain tumor growth in men by suppressing inflammation and stress hormone production. Analysis of over 1,300 men with glioblastoma found that supplemental testosterone was significantly associated with improved survival rates.
SourceNIH/Office of the Director·JournalNature·DateMay 6, 2026
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
SourceAlliance for Clinical Trials in Oncology·TypeRandomized controlled/clinical trial·DateMay 6, 2026
Meta Quest 3 512GB
Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.
Researchers from UH, Baylor College of Medicine and MD Anderson Cancer Center propose a new treatment approach for Crohn's disease by targeting the stress signal that fuels inflammation. They found that repurposing two existing cancer medications can promote natural repair and regeneration of the intestinal lining.
SourceUniversity of Houston·JournalGastro Hep Advances·DateApr 27, 2026
A new treatment using low-dose nivolumab injections into precancerous oral lesions significantly reduced lesion size and risk of cancer progression. The study showed a 60% average reduction in lesion size and complete pathologic response in six patients, with no dose-limiting side effects.
SourceUniversity of Texas M. D. Anderson Cancer Center·DateApr 21, 2026
The hospital is conducting a phase 2 clinical trial evaluating STAR0602, which activates the immune system to stop tumor growth across various cancers. The goal of this study is to identify safer and more effective treatments for people with advanced cancers.
SourceThe University of Texas at San Antonio Health Science Center·DateApr 15, 2026
GQ GMC-500Plus Geiger Counter
GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
SourceAlliance for Clinical Trials in Oncology·JournalJCO Oncology Advances·TypeRandomized controlled/clinical trial·DateApr 8, 2026
A study found that tumor DNA in patients' blood can predict whether breast cancer will return, especially after neoadjuvant treatment. Patients with detectable DNA at the end of treatment were 3.5 times more likely to relapse during follow-up.
SourceEuropean Organisation for Research and Treatment of Cancer·TypeObservational study·DateMar 26, 2026
A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.
SourceDartmouth Health·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateMar 25, 2026
A new analysis shows elinzanetant effectively relieves moderate-to-severe vasomotor symptoms (VMS) associated with endocrine therapy, regardless of the type of hormone treatment. The drug reduces VMS frequency and severity by blocking a protein that triggers these symptoms.
SourceEuropean Organisation for Research and Treatment of Cancer·TypeRandomized controlled/clinical trial·DateMar 25, 2026
Researchers successfully treated drug-resistant strains of herpes using doxorubicin, a known anticancer drug. The treatment works by targeting a pathway used by the virus, preventing infection and potentially saving lives for vulnerable patients.
SourceUniversity of Illinois Chicago·JournalDrug Resistance Updates·DateMar 24, 2026
Creality K1 Max 3D Printer
Creality K1 Max 3D Printer rapidly prototypes brackets, adapters, and fixtures for instruments and classroom demonstrations at large build volume.
A novel drug delivery system developed by Osaka Metropolitan University improves Paclitaxel absorption by binding to the lipocalin-type prostaglandin D synthase enzyme, enabling selective delivery to cancer tissues. The system demonstrates significant tumor suppression effects even after administration cessation.
SourceOsaka Metropolitan University·JournalACS Omega·TypeExperimental study·DateMar 16, 2026
Researchers have identified and resolved molecular bottlenecks to produce doxorubicin, a vital chemotherapy agent, resulting in a 180% increase in production. This breakthrough enables cost-effective manufacturing of essential antibiotics and anti-cancer agents, promising a cleaner and more reliable supply of life-saving medicines.
SourceUniversity of Turku·JournalNature Communications·DateMar 13, 2026
Researchers at Duke University have developed a technique using microbubbles and ultrasound to deliver large cancer drugs into cells, causing them to self-destruct. The technology, called SonoPIN, shows promise in precisely delivering therapeutics to cancer cells with minimal off-target effects.
SourceDuke University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateMar 13, 2026
Sky-Watcher EQ6-R Pro Equatorial Mount
Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.
Researchers discovered yaku'amide B induces CD9 degradation, a cancer stem cell-related protein, in addition to inhibiting ATP synthase, leading to cellular energy depletion and cancer cell suppression. This natural compound has potential as a new therapeutic approach for cancer treatment.
SourceTokyo University of Agriculture and Technology·JournalJournal of the American Chemical Society·TypeExperimental study·DateMar 11, 2026
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
SourceAlliance for Clinical Trials in Oncology·DateMar 11, 2026
Researchers discover a potential chemotherapy agent that causes cancer cells to release signals similar to those released by infected cells, triggering an immune response. This finding could lead to a new approach in cancer treatment, using lower doses of chemotherapy drugs to recruit the immune system as an ally.
SourceUniversity of Texas at Austin·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateMar 11, 2026
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
SourceAlliance for Clinical Trials in Oncology·DateMar 8, 2026
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
Approximately 40 cancer patients will receive LMP744 for five consecutive days, with biological analyses conducted on brain tissues before and after treatment. If results are favorable, treatment will continue for 12 cycles to evaluate parameters such as progression-free survival and overall survival.
Studies presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium highlight the growing potential of RPTs to improve cancer outcomes. A meta-analysis shows Lu-177 PSMA-617 consistently prolongs progression-free survival without adding severe side effects for patients with advanced prostate cancer.
SourceAmerican Society for Radiation Oncology·DateFeb 17, 2026
The conference aims to improve genetic studies, clinical best practices and community interventions to combat the increasing cancer incidence rates. It will bring together top cancer-focused minds to promote precision medicine and stimulate multidisciplinary collaborations for cancer solutions.
SourceThe University of Texas at San Antonio Health Science Center·DateFeb 17, 2026
Researchers have discovered a new mechanism by which an existing cancer drug can block the loss of BCMA molecules on cancer cells, allowing CAR T cell therapy to become effective again in some patients. The study shows that carfilzomib can prevent the degradation of BCMA and restore its presence on the surface of malignant plasma cells.
SourceTechnical University of Munich (TUM)·JournalBlood·TypeExperimental study·DateFeb 11, 2026
Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster and cheaper than before. This new technology enables researchers to assess which CAR T variants are most promising much more quickly, leading to safer and more targeted cancer treatments.
SourceTechnical University of Denmark·JournalNature Communications·DateFeb 4, 2026
GoPro HERO13 Black
GoPro HERO13 Black records stabilized 5.3K video for instrument deployments, field notes, and outreach, even in harsh weather and underwater conditions.
The PATINA trial demonstrates a significant progression-free survival benefit with palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. The study showed a median progression-free survival of 44.3 months, compared to 29.1 months in the control arm.
SourcePrECOG, LLC·JournalNew England Journal of Medicine·DateJan 29, 2026
Scientists at Northwestern University have determined the three-dimensional structures of rye pollen's cancer-fighting molecules, secalosides A and B. This breakthrough opens the door to exploring how these molecules interact with the immune system and could inspire new approaches to cancer therapy.
SourceNorthwestern University·JournalJournal of the American Chemical Society·DateJan 21, 2026
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
SourceAlliance for Clinical Trials in Oncology·TypeExperimental study·DateJan 12, 2026
A Mass General Brigham study identifies new mutations that emerge in tumor cells following treatment, driving resistance in patients with different types of cancer. The researchers found two main categories of mutations: those impairing p53 function and others disrupting drug binding, highlighting a path forward for overcoming resistance.
SourceMass General Brigham·JournalCancer Discovery·TypeObservational study·DateJan 12, 2026
Kestrel 3000 Pocket Weather Meter
Kestrel 3000 Pocket Weather Meter measures wind, temperature, and humidity in real time for site assessments, aviation checks, and safety briefings.
Researchers create a novel mathematical framework to control biological noise, enabling precise single-cell control. The 'Noise Robust Perfect Adaptation' technology suppresses stochastic fluctuations while maintaining stable average behavior, with promising applications in cancer therapy and synthetic biology.
SourceInstitute for Basic Science·JournalNature Communications·TypeComputational simulation/modeling·DateJan 2, 2026
A study published in EMBO Molecular Medicine has identified a combination of statins and phenothiazines that shows promise in treating aggressive neuroblastoma. The drug combination was found to impede tumour growth and improve survival rates in laboratory trials with mice.
SourceLund University·JournalEMBO Molecular Medicine·TypeComputational simulation/modeling·DateDec 29, 2025
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.
Celestron NexStar 8SE Computerized Telescope
Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.
A new oral endocrine therapy, giredestrant, has been shown to significantly lower the risk of breast cancer recurrence in early-stage HR-positive/HER2-negative patients. In a large clinical trial, patients treated with giredestrant were 30% less likely to have invasive disease recur or progress.
SourceUniversity of California - Los Angeles Health Sciences·DateDec 10, 2025
Researchers at the University of Plymouth will receive a £2.8 million funding boost to accelerate new treatments for low-grade brain tumors. The center aims to deepen understanding and translate knowledge into life-changing therapies.
Researchers at Insilico Medicine developed an AI-empowered dual-action PROTAC targeting PKMYT1, which induces degradation and inhibits kinase activity. The lead compound, D16-M1P2, exhibits high selectivity, potent anti-tumor activity, and favorable oral bioavailability.
SourceInSilico Medicine·JournalNature Communications·DateDec 1, 2025
Australian researchers have discovered a drug combination that can bypass the cellular defenses developed by neuroblastoma tumors, making it more effective against relapsed cases. The combination reduces tumor growth and extends survival time compared to standard treatment alone.
SourceGarvan Institute of Medical Research·JournalScience Advances·TypeExperimental study·DateNov 28, 2025
A new study reveals that kinase inhibitors can accelerate the degradation of targeted proteins, which is not a rare quirk but a common mechanism. This discovery could help design better drugs that remove kinases altogether or explain unexpected effects of existing therapies.
SourceCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences·JournalNature·TypeExperimental study·DateNov 26, 2025
AmScope B120C-5M Compound Microscope
AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.
A new study has developed a calcium-activated delivery system that enables more precise cancer treatment, reducing side effects and improving outcomes. The system uses a 'calcium switch' to target tumor cells, releasing a lethal payload deep within, while sparing healthy tissue.
SourceKTH, Royal Institute of Technology·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateNov 24, 2025
Experts warn that new drugs for advanced breast cancer are unaffordable and may lead to unequal treatment access worldwide. The consensus panel recommended prioritizing most effective treatments and using next-generation sequencing for personalized medicine.
SourceAssociação Advanced Breast Cancer Global Alliance·TypeCommentary/editorial·DateNov 9, 2025
Researchers have discovered a new way to understand cancer and its vulnerabilities by targeting FSP1, a protein that helps cancer cells survive. The study found that FSP1 inhibitors can effectively reduce the growth of metastatic melanoma cells in lymph nodes.
SourceHarvard T.H. Chan School of Public Health·JournalNature·TypeExperimental study·DateNov 5, 2025
The American Society for Radiation Oncology (ASTRO) has announced three winning research proposals for the 2025 ASTRO-AstraZeneca Small Cell Lung Cancer Therapy Challenge. The selected projects aim to improve therapies and outcomes for patients with limited-stage SCLC through immunotherapy and radiation techniques.
SourceAmerican Society for Radiation Oncology·DateNov 4, 2025
Aranet4 Home CO2 Monitor
Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.
Researchers developed TAMENDOX to supplement (Z)-endoxifen in patients with CYP2D6 enzyme deficiency, improving drug concentration and effectiveness. The new therapy was well-tolerated, showing promise as an alternative to aromatase inhibitors for premenopausal women.
SourceBosch Health Campus GmbH·JournalClinical Cancer Research·DateOct 16, 2025
A new clinical trial found that adding a PSMA-targeting agent to stereotactic radiation therapy doubled progression-free survival in patients with limited metastatic prostate cancer. The study also showed that the treatment delayed hormone therapy by 24 months and improved local control.
SourceAmerican Society for Radiation Oncology·DateSep 28, 2025
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
SourceAmerican Society for Radiation Oncology·DateSep 28, 2025
Davis Instruments Vantage Pro2 Weather Station
Davis Instruments Vantage Pro2 Weather Station offers research-grade local weather data for networked stations, campuses, and community observatories.
A recent analysis reveals a modest decline in new and additional opioid prescriptions for patients with cancer from 2016 to 2020. For patients with metastatic cancer, prescribing remained stable for those reporting any pain but declined steeply for those reporting no pain.
A new class of targeted therapy showed promise in treating head and neck squamous cell carcinoma (HNSCC) in pet cats, with 35% of patients experiencing controlled disease. The drug, which targets the transcription factor STAT3, also raised levels of PD-1, a protein associated with an immune response to cancer.
SourceCell Press·JournalCancer Cell·TypeRandomized controlled/clinical trial·DateAug 28, 2025
Researchers found that combining aramchol with regorafenib killed liver and colorectal cancer cells more effectively than either drug alone, triggering stress responses and disrupting survival pathways. The combination was especially effective in cells with a genetic variant called ATG16L1 T300.
SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateAug 19, 2025
A study at the Garvan Institute of Medical Research found that inactivation of a stress pathway makes ER+ breast cancer cells ignore stress signals, allowing them to evade treatment. The JNK pathway acts as a cellular alarm system, and its disruption leads to treatment resistance.
SourceGarvan Institute of Medical Research·JournalJournal of Experimental & Clinical Cancer Research·TypeExperimental study·DateAug 18, 2025
Apple iPad Pro 11-inch (M4)
Apple iPad Pro 11-inch (M4) runs demanding GIS, imaging, and annotation workflows on the go for surveys, briefings, and lab notebooks.
Researchers at Peking Union Medical College Hospital have developed bi-functional molecules combining PD-1 blockade with precision IL-2 delivery to revive 'sleepy' T cells. This combination enhances immune cell response, reducing toxicity and improving cancer treatment outcomes.
SourceScience China Press·JournalScience Bulletin·TypeLiterature review·DateAug 15, 2025